Danaher Corporation $DHR Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 22.4% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 614,167 shares of the conglomerate’s stock after acquiring an additional 112,316 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Danaher were worth $116,446,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Enterprise Financial Services Corp lifted its holdings in shares of Danaher by 1.4% in the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock worth $737,000 after acquiring an additional 46 shares during the last quarter. Kennebec Savings Bank increased its holdings in Danaher by 1.4% in the 4th quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock valued at $766,000 after purchasing an additional 46 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Danaher by 2.6% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock valued at $428,000 after purchasing an additional 47 shares during the period. High Note Wealth LLC raised its position in Danaher by 19.2% in the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock valued at $67,000 after purchasing an additional 47 shares during the period. Finally, First Command Advisory Services Inc. lifted its stake in Danaher by 4.4% during the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock worth $253,000 after purchasing an additional 47 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore restated an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Robert W. Baird cut their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Guggenheim lowered their target price on Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a report on Wednesday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 target price on shares of Danaher in a research report on Wednesday. Finally, TD Cowen cut their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Trading Down 0.3%

NYSE:DHR opened at $191.87 on Friday. The firm has a market cap of $134.88 billion, a PE ratio of 34.08, a price-to-earnings-growth ratio of 2.40 and a beta of 0.79. The stock has a fifty day moving average price of $185.64 and a 200 day moving average price of $197.04. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.52 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the prior year, the business earned $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. Sell-side analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. Danaher’s payout ratio is currently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.